Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery

• Published in: Journal of experimental & clinical cancer research 2023-05, Vol.42 (1), p.117-117, Article 117
• Main Authors: Long, Li, Xiong, Wei, Lin, Fenwang, Hou, Jiazhen, Chen, Guihua, Peng, Taoxing, He, Yihao, Wang, Rui, Xu, Qin, Huang, Yongzhuo
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Cancer; Care and treatment; CD8-Positive T-Lymphocytes; Colorectal cancer; Colorectal cancer liver metastasis; Colorectal Neoplasms - drug therapy; Cytotoxicity; Dendritic cells; Efficiency; Enzymes; Epithelial-Mesenchymal Transition; Epithelial-mesenchymal transition (EMT); Gastrointestinal diseases; Glycolysis; Health aspects; Humans; Hyaluronic Acid; Immune microenvironment; Kinases; Lactates; Lactic Acid; Liver Neoplasms - drug therapy; Lymphocytes; Metabolism; Metastasis; Mice; Nanoparticles; Proteins; Pyruvate kinase M2 (PKM2); Shikonin; Stem cells; T cells; Transforming growth factors; Tumor Microenvironment; Tumors
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-023-02688-z

There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribute to the progression of CRLM. A main glycolytic enzyme pyruvate Kinase M2 (PKM2) is highly expressed in colorectal cancer and CRLM, and thus can be a potential therapeutic target. A therapeutic strategy was proposed and the shikonin-loaded and hyaluronic acid-modified MPDA nanoparticles (SHK@HA-MPDA) were designed for CRLM therapy via PKM2 inhibition for immunometabolic reprogramming. The treatment efficacy was evaluated in various murine models with liver metastasis of colorectal tumor. SHK@HA-MPDA achieved tumor-targeted delivery via hyaluronic acid-mediated binding with the tumor-associated CD44, and efficiently arrested colorectal tumor growth. The inhibition of PKM2 by SHK@HA-MPDA led to the remodeling of the tumor immune microenvironment and reversing EMT by lactate abatement and the suppression of TGFβ signaling; the amount of cytotoxic effector CD8 T cells was increased while the immunosuppressive MDSCs decreased. The work provided a promising targeted delivery strategy for CRLM treatment by regulating glycolysis, EMT, and anticancer immunity. An immunometabolic strategy for treating colorectal cancer liver metastases using the shikonin-loaded, hyaluronic acid-modified mesoporous polydopamine nanoparticles (SHK@HA-MPDA) via glycolysis inhibition, anticancer immunity activation, and EMT reversal. SHK@HA-MPDA can inhibit cytoplasmic PKM2 and glycolysis of the tumor and reduce lactate flux, and then activate the DCs and remodel the tumor immune microenvironment. The reduced lactate flux can reduce MDSC migration and suppress EMT.